David Domzalski has served as Chief Executive Officer since July 2017. Mr. Domzalski has been with Foamix since April 2014, and previously served as the President of Foamix Pharmaceuticals Inc. (U.S. subsidiary). He has 25 years of industry experience, previously holding positions as Vice President Sales and Marketing at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President Sales and Marketing at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Chief Financial Officer & Country Manager
Ilan Hadar has served as Chief Financial Officer since February 2014 and as the Israel Country Manager since July 2017. Mr. Hadar has over 20 years of experience in executive financial positions, previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager, Accounting and Reporting at the Israeli subsidiary of HP from 2007 to 2011, and prior to that as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a B.A. in business administration and economics and an MBA from The Hebrew University of Jerusalem.
Chief Commercial Officer
Matt Wiley has served as Chief Commercial Officer since November 2018. Mr. Wiley brings over 20 years of commercial and brand leadership experience, previously holding positions as Vice President of Marketing and Business Unit Lead at Jazz Pharmaceuticals from 2012 to 2018, as Vice President of Marketing at Azur Pharma from 2007 to 2012, and prior to Azur, holding positions of increasing responsibility in sales, sales training and marketing with Guilford/MGI Pharma, Salix Pharmaceuticals, Cephalon and Rhone-Poulenc Rorer. Mr. Wiley holds a BA in English from Syracuse University.
Dr. Iain Stuart
Chief Scientific Officer
Iain Stuart, Ph.D., has served as Chief Scientific Officer since January 2019. Dr. Stuart has been with Foamix since October 2016, and previously served as Senior Vice President of Research and Development. He has over 19 years of industry experience, previously holding various positions at LEO Pharma, Inc. from 2008 to 2016 including Director of Preclinical Development, Director of Clinical Operations, Vice President of R&D Project Management, and most recently, Vice President of Medical Strategy and Scientific Affairs. Prior to LEO Pharma, Dr. Stuart served as Senior Study Director at Inveresk Research (now Charles River), and as Project Manager, Pharmaceutical Development at Cyclacel, Inc. Dr. Stuart has a PhD and 1st Class Honors BSc. in Chemistry from Glasgow Caledonian University and was a Post-Doctoral Fellow in Medicinal Chemistry at the University of Strathclyde.
General Counsel & Chief Legal Officer
Mutya Harsch has served as General Counsel and Chief Legal Officer since January 2019. Ms. Harsch has been with Foamix since January 2018, and previously served as the General Counsel and Senior Vice President of Legal Affairs. She has over 19 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions at Cooley LLP from 2015 to 2017, as a corporate lawyer at Davis Polk & Wardwell from 2005 to 2015 and from 1999 to 2003, and as Assistant General Counsel at Warner Chilcott from 2003 to 2005. Ms. Harsch received her J.D. and B.A. from the University of California at Berkeley.
Senior Vice President, Global Human Resources
Ray Steitz has served as Senior Vice President of Global Human Resources since November 2018. Mr. Steitz has over 30 years of human resource experience, previously holding positions as Senior Vice President of Human Resources at Olam Americas Inc. from 2010 to 2018, as Global Vice President of Human Resources at Warner Chilcott from 2001 to 2010, and prior to Warner Chilcott, holding various HR leadership and generalist roles at Unilever. Mr. Steitz holds a BS in Business from Rider University.
Dr. Russell Elliott
Senior Vice President, Pharmaceutical Development
Russell Elliott, Ph.D., has served as Senior Vice President of Pharmaceutical Development since January 2019. Dr. Elliott has been with Foamix since May 2016, and previously served as the Vice President of Drug Development. He has over 25 years of industry experience, previously holding positions as Head of Skincare Technology at Lonza Inc. from 2015 to 2016, Head of Product Development at Stiefel (a GSK Company) from 2011 to 2014, Head of the Center of Excellence for Liquids, Cream and Ointments at GSK (UK) from 2007 to 2011, and Principal Scientist at Procter & Gamble from 1992 to 2007. He has filed more than 60 patent applications in the area of skincare formulation. Dr. Elliott has a PhD and MA from The University of Oxford and is a Fellow of the Royal Society of Chemistry.
Vice President, Regulatory Affairs
Deepa Desai has served as Vice President of Regulatory Affairs since March 2019. Ms. Desai has over 25 years of industry experience, previously holding positions as Senior Director of Regulatory Affairs at DBV Technologies from 2018 to 2019, Director of Global Regulatory Affairs at Radius Health from 2015 to 2018, Director of Regulatory Affairs at Actavis (formerly Warner Chilcott) from 2003 to 2015, and various positions in Quality Management and Regulatory Affairs at Hoffman-La Roche from 1992 to 2003. Ms. Desai holds a B.A., Biological Sciences from Rutgers University and M.S., Biological Science, with a minor in Business Administration from Seton Hall University.
Vice President, Intellectual Property
David Schuz has served as Vice President of Intellectual Property since August 2017. Mr. Schuz has led the Intellectual Property function at Foamix since July 2006. Mr. Schuz has 20 years of industry experience in the field of pharmaceuticals and biotechnology intellectual property, previously holding positions at Biotechnology General Israel Ltd. and Savient Pharmaceuticals, Inc. between 1999 and 2006, including Vice President from 2003. Mr. Schuz holds an LL.M. from the London School Economics; a Certificate in Patent Law, Queen Mary London University; an M. Phil. (Biochemistry), and a Diploma of Pharmacology, both from Cambridge University; and a B.Sc. Hons. (Chemistry) from Manchester University.
Vice President, Quality
Bonnie Pappacena has served as Vice President of Quality since September 2017. Ms. Pappacena has over 30 years of quality and compliance expertise spanning across good clinical practices (GCP), good laboratory practices (GLP) and good manufacturing practices (GMP) for clinical supplies and commercial product and good pharmacovigilance practices (GVP) regulations. Ms. Pappacena has worked primarily in the pharmaceutical industry and her experience includes drug product as well as combination product development. Prior to Foamix, Ms. Pappacena served as Vice President, Quality at G&W Laboratories from 2016 to 2017, Vice President, Quality at Turing Pharmaceuticals from 2015 to 2016 and Vice President, Quality at Acorda Therapeutics from 2009 to 2015. Ms. Pappacena also held positions of increasing quality responsibility at Schering Plough Research Institute and Lederle (Wyeth). Ms. Pappacena has a B.S./B.A in Psychology/Philosophy from the University of Scranton and an M.S. in Experimental Psychology from Villanova University.